Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

West Boca Medical Center is the 1st Hospital Serving Palm Beach & North Broward Counties to use NICVIEW 2™ in NICU to Keep Families and their Newborn Connected

February 23, 2021

West Boca Medical Center* notes when a new bundle of joy requires extra special medical care in the Level III Neonatal Intensive Care Unit, parents and extended family might feel overwhelmed.

West Boca Medical Center’s medical staff work hard to relieve those fears, by caring for any premature or at-risk baby.

Further enhancing this care, the hospital is now the only one in Palm Beach and North Broward County, to have installed the NICVIEW 2™ Live Streaming Camera Systems in its Level III NICU, the highest level of care available.  Parents and their family members can now see their baby at all times, even when they cannot be there in person.  The password-protected camera provides parents and their family members a secure virtual window to their newborn in the NICU.

“This new and protected technology is giving families and loved ones another way to connect with their baby even when they can’t be present all of the time in our Level III NICU,” said George Rizzuto, chief executive officer of West Boca Medical Center.  “We understand the challenges families face when their child is in the NICU, often unexpectedly, so we are trying to take concerns about separation out of the equation.  Families can see their baby at any time, and feel secure knowing they are getting the very best care possible at our hospital.”

Some of the benefits of the NICVIEW 2™ include:

  • On-Demand HD Quality Video Streaming
  • Encrypted Password Protected Software
  • Available for families 24/7

*West Boca Medical Center is the only 5-Star Hospital in Labor and Delivery, and the only Level III NICU in Boca Raton.

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy